These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9174182)

  • 1. Modeling the response of pneumonia to antimicrobial therapy.
    Hyatt JM; Luzier AB; Forrest A; Ballow CH; Schentag JJ
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1269-74. PubMed ID: 9174182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical examination of dual individualization principles. (III): Development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients.
    Luzier A; Goss TF; Cumbo TJ; Schentag JJ
    Ann Pharmacother; 1992 Nov; 26(11):1358-65. PubMed ID: 1477437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.
    Goss TF; Forrest A; Nix DE; Ballow CH; Birmingham MC; Cumbo TJ; Schentag JJ
    Ann Pharmacother; 1994; 28(7-8):863-8. PubMed ID: 7949501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
    Highet VS; Forrest A; Ballow CH; Schentag JJ
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
    Schentag JJ; Nix DE; Adelman MH
    DICP; 1991 Oct; 25(10):1050-7. PubMed ID: 1803788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
    Schentag JJ
    Scand J Infect Dis Suppl; 1990; 74():218-34. PubMed ID: 2097710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nosocomial pneumonia with isolation of anaerobic bacteria in ICU patients: therapeutic considerations and outcome.
    Robert R; Grollier G; Doré P; Hira M; Ferrand E; Fauchère JL
    J Crit Care; 1999 Sep; 14(3):114-9. PubMed ID: 10527248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
    Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
    Forrest A; Nix DE; Ballow CH; Goss TF; Birmingham MC; Schentag JJ
    Antimicrob Agents Chemother; 1993 May; 37(5):1073-81. PubMed ID: 8517694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study.
    Manhold C; von Rolbicki U; Brase R; Timm J; von Pritzbuer E; Heimesaat M; Kljucar S
    Intensive Care Med; 1998 Dec; 24(12):1327-30. PubMed ID: 9885888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia.
    Pryka R; Kowalsky S; Haverstock D
    Clin Ther; 1998; 20(1):141-55. PubMed ID: 9522111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group.
    Anzueto A; Niederman MS; Haverstock DC; Tillotson GS
    Clin Ther; 1997; 19(5):989-1001. PubMed ID: 9385486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
    Caldwell JW; Singh S; Johnson RH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.